RADICAVA | New treatment for MND listed on the PBS

Published: May 2025

From today, 1 May 2025, a new treatment option for people with MND has been listed on the Pharmaceutical Benefits Scheme (PBS).

RADICAVA® IV infusion (edaravone) is now available on prescription for people with ALS (the most common form of MND).

RADICAVA® is administered as an intravenous infusion by a health professional, usually at an infusion clinic at either a public or private hospital. Each infusion takes approximately an hour.

In the first month of treatment, infusions must be given every day for 14 consecutive days. In subsequent months, this reduces to 10 infusions in a 14 day period followed by 14 days of no treatment.

RADICAVA® must be first prescribed within two years of symptom onset.

To find out more, visit the edaravone section on our Medication for MND web page.

For more information about RADICAVA® IV infusion, contact your neurologist or refer to the Consumer Medicine Information summary on the TGA’s website.